Last updated: February 22, 2026
What is the drug associated with NDC 43068-0108?
NDC 43068-0108 corresponds to Vemurafenib (Zelboraf), a targeted therapy approved for the treatment of melanoma with BRAF V600 mutations.
Market Overview
Vemurafenib competes in the oncology market for melanoma treatments. It is part of a growing segment of precision medicines targeting genetic mutations. The global melanoma drug market has seen steady growth driven by increased diagnosis rates and expanding indications.
Key Market Dynamics
-
Growth Drivers:
- Rising melanoma incidence: 7.2 cases per 100,000 globally (GLOBOCAN, 2020).
- Adoption of BRAF inhibitor therapies: 70-80% of advanced melanoma cases harbor BRAF mutations.
- Advances in combination therapies: Vemurafenib combined with cobimetinib or binimetinib.
- Regulatory approvals for expanded indications, including adjuvant settings.
-
Competitive Landscape:
- Other BRAF inhibitors: Dabrafenib (Tafinlar) and encorafenib (Braftovi).
- MEK inhibitors: Trametinib (Mekinist), cobimetinib.
- Immunotherapies: Pembrolizumab, nivolumab.
Market Size
The U.S. oncology drug market for melanoma was valued at approximately $1.2 billion in 2022, with Vemurafenib holding around 20% market share of targeted therapies.
Pricing Overview
Historical Pricing Data
- Wholesale Acquisition Cost (WAC): Approx. $13,000–$15,000 per month in the U.S.
- Average Price per Patient (Annual): Estimated at $150,000, considering dosing and administration schedules.
Price Trends and Factors
- Price Stability: Targeted therapies like Vemurafenib have maintained stable prices over recent years due to their patent protection.
- Generic Competition: Not applicable currently; patent expiration is not imminent (patent expiry around 2027).
- Reimbursement Policies: Insurance coverage primarily drives patient access, with some variations depending on the healthcare system.
Price Projection (Next 5 Years)
| Year |
Estimated WAC per Month |
Rationale |
| 2023 |
$13,500 |
Current market level; inflation slight upward trend. |
| 2024 |
$13,700 |
Slight increase accounting for inflation and value-based pricing initiatives. |
| 2025 |
$13,900 |
Stabilization with continued inflation. |
| 2026 |
$14,000 |
No significant patent challenges expected. |
| 2027 |
$14,200 |
Anticipated patent expiration, potential price reduction or generic entry may occur beyond this year. |
Note: These projections assume no major policy changes, patent challenges, or entry of generic competitors before 2027.
Regulatory and Patent Outlook
- Patent protection prevents generics until approximately 2027.
- Orphan drug status and exclusivity periods delay generic entry.
- Biosimilar or generic competition expected post-2027 could reduce prices by 40-60%.
Potential Market Risks
- Emergence of new, more effective BRAF/MEK inhibitors.
- Expiration of patent rights leading to generic competition.
- Changes in healthcare reimbursement policies affecting pricing.
Summary
Vemurafenib remains a high-value targeted therapy in melanoma, with stable prices and a sizable market share. Pricing projections suggest marginal annual increases aligned with inflation, with significant downward pressure expected after patent expiration in 2027.
Key Takeaways
- NDC 43068-0108 (Vemurafenib) operates in a $1.2 billion U.S. melanoma drug market.
- Current WAC prices are approximately $13,500/month.
- Market growth driven by increased melanoma incidence and combination therapy adoption.
- Patent expiry anticipated in 2027 could lead to substantial price reductions.
- Continued innovation and patent protection sustain current pricing until generic entry.
FAQs
1. What is the primary indication for Vemurafenib?
Treats melanoma with BRAF V600 mutations.
2. How does Vemurafenib compare in price to competitors?
Pricing is similar, with approximate WAC around $13,500/month, slightly below dabrafenib but comparable overall.
3. When is generic Vemurafenib expected?
Post-2027, following patent expiry.
4. What factors could disrupt the current market?
Emergence of new therapies, biosimilar entry, or significant regulatory changes.
5. How might future pricing be affected?
Potential reductions post-patent expiration due to biosimilar competition; price increases are unlikely without new indications or formulations.
References
- GLOBOCAN. (2020). Global Cancer Statistics 2020. International Agency for Research on Cancer.
- IQVIA. (2022). Global Oncology Market Data.
- FDA. (2018). Vemurafenib (Zelboraf) approval documents.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for oncology drugs.
- Evaluate Pharma. (2023). Oncology drug market forecasts.
